NewAmsterdam Pharma Company N.V Stock Price, News & Analysis

NewAmsterdam Pharma (Nasdaq: NAMS) announced inducement option grants covering an aggregate of 40,000 ordinary shares to two non‑executive new hires under the 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The options carry an exercise price of $39.61, equal to the closing Nasdaq price on December 1, 2025 (grant date). The shares subject to the options vest over four years: 25% on the one‑year anniversary of each vesting commencement date, then the balance in 36 equal monthly installments, subject to continued service. The options are governed by the 2024 Inducement Plan and individual option award agreements.

NewAmsterdam Pharma (Nasdaq: NAMS) announced that company management will participate in three investor conferences in early December 2025: the 8th Annual Evercore Healthcare Conference on Dec 2, 2025 (Ian Somaiya, CFO, fireside chat at 3:50 PM ET); Citi 2025 Global Healthcare Conference on Dec 3, 2025 (Michael Davidson, CEO, and Ian Somaiya, CFO, fireside chat at 3:15 PM ET); and the Piper Sandler 37th Annual Healthcare Conference on Dec 4, 2025 (Michael Davidson, CEO, and Ian Somaiya, CFO, fireside chat at 8:00 AM ET).

Live webcasts and archived replays of the fireside chats will be available via the company’s investor relations website at ir.newamsterdampharma.com.

NewAmsterdam Pharma (Nasdaq: NAMS) announced that its Compensation Committee approved inducement option grants covering 18,000 ordinary shares to one non-executive new hire under the 2024 Inducement Plan and Nasdaq Listing Rule 5635(c)(4).

The options carry an exercise price of $37.00, equal to the Nasdaq closing price on the grant date of November 3, 2025. Vesting occurs over four years: 25% on the one-year anniversary of the vesting commencement date, then the remainder in 36 equal monthly installments, subject to continued service. Grants are subject to the 2024 Inducement Plan and the related option award agreement.

NewAmsterdam Pharma (Nasdaq: NAMS) reported third-quarter 2025 results and a corporate update focused on obicetrapib development and regulatory progress.

Key points: EMA accepted MAAs for obicetrapib 10 mg monotherapy and a 10/10 mg obicetrapib/ezetimibe FDC; pooled BROADWAY and BROOKLYN analyses were published in JACC and a BROADWAY Alzheimer’s substudy in Journal of Prevention of Alzheimer's Disease. Cash, cash equivalents and marketable securities were $756.0 million at September 30, 2025; Q3 revenue was $0.3M and net loss was $72.0M.

NewAmsterdam Pharma (Nasdaq: NAMS) will present additional safety and efficacy results from its pivotal Phase 3 BROOKLYN, BROADWAY and TANDEM trials at the 2025 American Heart Association Scientific Sessions in New Orleans, November 7–10, 2025.

Oral presentation: ‘‘CETP Inhibition with Obicetrapib Produces Substantial Reductions in LDL Particles: Pooled Analysis of BROOKLYN and BROADWAY’’ by John Kastelein on Nov 9, 2025 at 10:15am CT. Digital poster: obicetrapib plus ezetimibe data by Jose Inia on Nov 10, 2025 at 10:59am CT. Management will join three investor conference fireside chats Nov 11–19, 2025, with live webcasts and archived replays on the company IR site.

Caristo Diagnostics was chosen as the worldwide imaging core lab for NewAmsterdam Pharma (NASDAQ: NAMS) REMBRANDT Cardiovascular Imaging Trial announced Oct 14, 2025. Caristo will oversee all coronary plaque and inflammation measurements and monitoring across the study.

REMbrandT is a placebo-controlled, double-blind, randomized trial recruiting at 50 sites in 7 countries to assess obicetrapib+ezetimibe FDC. The primary endpoint is percent change in total noncalcified coronary atherosclerotic plaque volume (NCPV) at 18 months. Secondary endpoints include percent change in LDL-C and change in Caristo's proprietary FAI-Score for coronary inflammation.

NewAmsterdam Pharma (NASDAQ:NAMS), a late-stage clinical biopharmaceutical company focused on developing oral, non-statin medicines for cardiovascular disease patients, has announced its participation in the Stifel 2025 Virtual Cardiometabolic Forum.

The company's Chief Scientific Officer, John Kastelein, and EVP of Investor Relations, Matthew Philippe, will engage in a virtual fireside chat on September 30, 2025, at 11:00 a.m. ET. Investors can access the live webcast through NewAmsterdam's investor relations website, with an archived replay available afterward.

NewAmsterdam Pharma (NASDAQ: NAMS), a late-stage biopharma company focused on developing oral, non-statin medicines for cardiovascular disease patients, has announced its participation in multiple scientific and investor events in September 2025.

The company will present pooled safety and efficacy data from its Phase 3 BROADWAY and BROOKLYN trials for obicetrapib at the European Society of Cardiology Congress in Madrid. Additionally, management will participate in three investor conferences: Citi's Biopharma Back to School Summit, Cantor Global Healthcare Conference, and Wells Fargo Healthcare Conference.

NewAmsterdam Pharma (NASDAQ:NAMS) and Piramal Pharma Solutions announced the opening of a dedicated oral solid dosage (OSD) manufacturing suite at Piramal's Sellersville, Pennsylvania facility. The multi-million-dollar investment aims to enhance production capabilities for NewAmsterdam's fixed dose combination (FDC) of obicetrapib and ezetimibe, a non-statin cholesterol medication.

The new suite features advanced capabilities for granulation, compression, tableting, and coating, specifically designed for multi-layer tablet production. The collaboration extends beyond Sellersville, with support from Piramal's facilities in Ahmedabad and Pithampur, India. The investment is expected to create over 20 new jobs at the Sellersville site over the next five years.